Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT. J of Skin. 2026;10(2):s762. doi:10.25251/g776yf41